1. Chromosomes and Gene Expression

Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers

  1. Timothy W R Kelso
  2. Devin K Porter
  3. Maria Luisa Amaral
  4. Maxim N Shokhirev
  5. Christopher Benner
  6. Diana C Hargreaves  Is a corresponding author
  1. Salk Institute for Biological Studies, United States
  2. University of California, San Diego, United States
https://doi.org/10.7554/eLife.30506
Share this article
Cite this article
  1. Timothy W R Kelso
  2. Devin K Porter
  3. Maria Luisa Amaral
  4. Maxim N Shokhirev
  5. Christopher Benner
  6. Diana C Hargreaves
(2017)
Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers
eLife 6:e30506.
https://doi.org/10.7554/eLife.30506
  2. Download BibTeX
  3. Download .RIS

Abstract

ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, is frequently mutated in cancer. Deficiency in its homolog ARID1B is synthetically lethal with ARID1A mutation. However, the functional relationship between these homologs has not been explored. Here we use ATAC-seq, genome-wide histone modification mapping, and expression analysis to examine colorectal cancer cells lacking one or both ARID proteins. We find that ARID1A has a dominant role in maintaining chromatin accessibility at enhancers, while the contribution of ARID1B is evident only in the context of ARID1A mutation. Changes in accessibility are predictive of changes in expression and correlate with loss of H3K4me and H3K27ac marks, nucleosome spacing, and transcription factor binding, particularly at growth pathway genes including MET. We find that ARID1B knockdown in ARID1A mutant ovarian cancer cells causes similar loss of enhancer architecture, suggesting that this is a conserved function underlying the synthetic lethality between ARID1A and ARID1B.

Data availability

The following data sets were generated
The following previously published data sets were used
    1. Stamatoyannopoulos J
    (2010) Stam_HCT-116_1
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSM736600).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM736600
    1. Allen MA
    2. Galbraith MD
    (2012) GRO-seq from HCT116 cells
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE38140).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38140
    1. ENCODE DCC
    (2012) HudsonAlpha_ChipSeq_HCT-116_FOSL1_(SC-183)_v042211.1
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSM1010756).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1010756
    1. ENCODE DCC
    (2012) HudsonAlpha_ChipSeq_HCT-116_CTCF_(SC-5916)_v042211.1
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSM1010903).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1010903
    1. ENCODE DCC
    (2012) HudsonAlpha_ChipSeq_HCT-116_ATF3_v042211.1
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSM1010757).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1010757
    1. ENCODE DCC
    (2012) HudsonAlpha_ChipSeq_HCT-116_JunD_v042211.1
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSM1010847).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1010847
    1. ENCODE DCC
    (2012) GIS-Ruan_ChiaPet_HCT-116_Pol2
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSM970210).
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM970210

Article and author information

Author details

  1. Timothy W R Kelso

    Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Devin K Porter

    Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Maria Luisa Amaral

    The Razavi Newman Integrative Genomics and Bioinformatics Core Facility, Salk Institute for Biological Studies, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Maxim N Shokhirev

    The Razavi Newman Integrative Genomics and Bioinformatics Core Facility, Salk Institute for Biological Studies, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Christopher Benner

    Department of Medicine, University of California, San Diego, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Diana C Hargreaves

    Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, United States
    For correspondence
    dhargreaves@salk.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3724-3826

Funding

National Institutes of Health (R00 CA184043-03)

  • Diana C Hargreaves

V Foundation for Cancer Research (V2016-006)

  • Diana C Hargreaves

Genentech Foundation (#G-37246)

  • Timothy W R Kelso

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Kelso et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,195
    views
  • 1,755
    downloads
  • 145
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Timothy W R Kelso
  2. Devin K Porter
  3. Maria Luisa Amaral
  4. Maxim N Shokhirev
  5. Christopher Benner
  6. Diana C Hargreaves
(2017)
Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers
eLife 6:e30506.
https://doi.org/10.7554/eLife.30506

Share this article

https://doi.org/10.7554/eLife.30506

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Chromosomes and Gene Expression

    The conserved ATPase PCH-2 controls the number and distribution of crossovers by antagonizing their formation in Caenorhabditis elegans

    Bhumil Patel, Maryke Grobler ... Needhi Bhalla
    Research Article

    Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.

    1. Cancer Biology
    2. Chromosomes and Gene Expression

    Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

    Ashley L Cook, Surojit Sur ... Nicolas Wyhs
    Research Article

    Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression

    Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

    Kira A Cozzolino, Lynn Sanford ... Dylan J Taatjes
    Research Article

    Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.